Unilife Corp

Unilife — Q3 2012 Earnings Presentation

18 slides from Unilife's earnings presentation, Apr 26, 2012

  1. Slide 1: Third Quarter 2012 Earnings Conference Call

    Third Quarter 2012 Earnings Conference Call April 26, 2012 Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our mana

  3. Slide 3: Corporate Overview

    Corporate Overview Alan Shortall Chief Executive Officer

  4. Slide 4: Making rapid progress to build shareholder value on all fronts

    Corporate Update Making rapid progress to build shareholder value on all fronts Strengthening commercial pipeline across multiple customers Commercial supply contracts for Unifill syringe on track from mid-year Significant activity across all device platforms Increased expenditure for March Quarter

  5. Slide 5: A Diversified, Differentiated Portfolio

    A Diversified, Differentiated Portfolio Unifill Unitract Auto-Infusors Unifill Select Rita Auto Injector EZMix

  6. Slide 6: The Unifill syringe

    The Unifill syringe Continued supply to current and new customers Anticipated signing of supply contracts from 2nd half of 2012 Increasing production capacities in line with market demands

  7. Slide 7: AutoInfusors

    AutoInfusors Wearable, disposable devices for subcutaneous self- administration of large volume doses (i.e. 2mL to 15mL) Platform expanding rapidly in response to customer demands Supplied to multiple parties for evaluations and user studies Expect to enter commercial partnerships for human clinical

  8. Slide 8: Specialized Devices

    Specialized Devices First GMP-compliant batch of first specialized device for targeted organ delivery ready to be shipped Global pharmaceutical company to use device in human clinical drug trials scheduled to occur later this year Unilife recognized revenue of $566,000 during the March Quarter as pa

  9. Slide 9: Drug Reconstitution Delivery Systems

    Drug Reconstitution Delivery Systems Only multi-chamber prefilled reconstitution syringe with integrated safety Minimal steps for reconstitution and injection compared to conventional systems Many emerging opportunities for use with liquid-dry and liquid-liquid combinations EZMix Dual or Multi-Chamb

  10. Slide 10: Rita Auto-Injector

    Rita Auto-Injector Single-use disposable system for patient self- injection Only auto-injector with true end-of-dose indicators (audible, tactile, visual) Compact size relative to conventional devices Strong market interest Various customization options Unilife Rita Conventional Auto-Injector

  11. Slide 11: R&D Investment Driven by Customer Needs

    R&D Investment Driven by Customer Needs SG&A has remained flat to down reflecting cash conservatism R&D investment reflects: Market demand and commercial interest Continual development of our product pipeline Many development programs in line for partner funding

  12. Slide 12: Financial Data Overview

    Financial Data Overview Rich Wieland Chief Financial Officer

  13. Slide 13: Financial Data - Fiscal 3rd Quarter 2012

    Revenues for the quarter of $1.3M, compared to $0.7M for 3Q 2011 Industrialization and development fees increased $0.6M related to the clinical development and supply of a novel device for targeted organ delivery Financial Data - Fiscal 3rd Quarter 2012

  14. Slide 14: Financial Data - Fiscal 3rd Quarter 2012 Continued

    Net loss for the quarter was $14.9M, or $0.21 per diluted share, compared to a net loss of $12.5M, or $0.20 per diluted share for 3Q 2011 R&D expenses increased by $3.9M due to additional payroll costs and expenditures related to the development of additional advanced drug delivery devices Partially

  15. Slide 15: Financial Data - Fiscal 3rd Quarter 2012 Continued

    Adjusted net loss of $10.7M, or $0.15 per diluted share, compared to an adjusted net loss of $9.3M, or $0.15 per diluted share for 3Q 2011 Excludes approx. $4.2M in non-cash share-based compensation expense, depreciation and amortization and interest expense compared to $3.2M in non-cash items in 3Q

  16. Slide 16: Looking Forward

    Looking Forward Alan Shortall Chief Executive Officer

  17. Slide 17: Looking Forward

    Committed to drive shareholder value by: Building partnerships with an expanding network of customers Accelerating commercialization of our diversified device portfolio Expanding production capabilities in-line with customer demands Investing in R&D and production while keeping SG&A flat On track to

  18. Slide 18: Questions

    Questions

Unilife — Q3 2012 Earnings Presentation on 6ix